Business
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CARLSBAD, Calif., March 05, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its fourth quarter and full year 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/bd316ec2dd3486cdc5067a939a4db235"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G8zxabqdPh8mNbLOBjxh6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bd316ec2dd3486cdc5067a939a4db235","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EUbDDr6GvkQF3UiAptGIYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/bd316ec2dd3486cdc5067a939a4db235","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025","length":129,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successfully Demonstrated the High-Scale Production Potential of Our Proprietary AlloSCOPE™ Manufacturing Platform","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated Manufacturing Scale Research Project in Type 1 Diabetes","length":65,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Treated First-Ever Chronic SCI Patient in OPC1 DOSED Device Safety Study","length":72,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Current Cash and Equivalents Expected to Support Operations Into Second Quarter 2028","length":84,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":728,"olType":false},{"type":"text","content":"CARLSBAD, Calif., March 05, 2026--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions,...